Table 3.
Efficacy.
| N | % | |
|---|---|---|
| Rate of overall survival at 3 months | ||
| Alive at 3 months | 8 | 44 |
| Not alive at 3 months | 10 | 56 |
| Best response iRANO | ||
| Complete response | 1 | 5.6 |
| Stable disease | 7 | 38.9 |
| Progressive disease | 4 | 22.2 |
| Not evaluablea | 6 | 33.3 |
| Best response RECISTb | ||
| Partial response | 1 | 5.6 |
| Stable disease | 3 | 16.7 |
| Progressive disease | 3 | 16.7 |
| Not evaluablea | 11 | 61.1 |
aIncludes cases where there is no evaluable disease at baseline or follow-up exams or where restaging scans not obtained.
bResponses as assessed by immune-related response criteria (irRC) were consistent with RECIST criteria.